Susquehanna International Group
CRBP icon

Susquehanna International Group’s Corbus Pharmaceuticals CRBP Stock Holding History

Susquehanna International Group’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.13M Buy
333,415
+105,589
+46% +$889K ﹤0.01% 5188
2025
Q4 		$1.85M Buy
227,826
+158,580
+229% +$1.96M ﹤0.01% 5811
2025
Q3 		$876K Buy
69,246
+25,914
+60% +$246K ﹤0.01% 7662
2025
Q2 		$299K Buy
43,332
+25,114
+138% +$182K ﹤0.01% 10342
2025
Q1 		$96.7K Sell
18,218
-11,596
-39% -$102K ﹤0.01% 11563
2024
Q4 		$352K Sell
29,814
-996
-3% -$16.7K ﹤0.01% 9474
2024
Q3 		$636K Buy
30,810
+24,972
+428% +$1.28M ﹤0.01% 7900
2024
Q2 		$264K Buy
+5,838
New +$246K ﹤0.01% 9743
2023
Q1 		– Sell
-5,247
Closed -$23K – 12665
2022
Q4 		$17.4K Buy
5,247
+2,138
+69% +$8.23K ﹤0.01% 11806
2022
Q3 		$15K Sell
3,109
-117
-4% -$825 ﹤0.01% 12694
2022
Q2 		$24K Sell
3,226
-19,727
-86% -$191K ﹤0.01% 12310
2022
Q1 		$366K Sell
22,953
-17,988
-44% -$238K ﹤0.01% 9759
2021
Q4 		$756K Buy
40,941
+10,169
+33% +$275K ﹤0.01% 8033
2021
Q3 		$942K Buy
30,772
+8,240
+37% +$325K ﹤0.01% 7708
2021
Q2 		$1.24M Sell
22,532
-16,393
-42% -$910K ﹤0.01% 7155
2021
Q1 		$2.3M Buy
38,925
+17,033
+78% +$1.12M ﹤0.01% 5586
2020
Q4 		$821K Sell
21,892
-307
-1% -$11.5K ﹤0.01% 7171
2020
Q3 		$1.2M Buy
22,199
+21,114
+1,946% +$3.82M ﹤0.01% 5679
2020
Q2 		$273K Sell
1,085
-5,556
-84% -$1.12M ﹤0.01% 8509
2020
Q1 		$1.04M Sell
6,641
-4,037
-38% -$682K ﹤0.01% 5306
2019
Q4 		$1.75M Buy
10,678
+9,787
+1,098% +$1.45M ﹤0.01% 4546
2019
Q3 		$130K Sell
891
-6,186
-87% -$1.08M ﹤0.01% 9412
2019
Q2 		$1.47M Buy
7,077
+2,756
+64% +$590K ﹤0.01% 4813
2019
Q1 		$901K Buy
4,321
+2,790
+182% +$615K ﹤0.01% 5229
2018
Q4 		$268K Buy
1,531
+261
+21% +$52.1K ﹤0.01% 7204
2018
Q3 		$288K Sell
1,270
-1,015
-44% -$164K ﹤0.01% 7560
2018
Q2 		$346K Sell
2,285
-3,371
-60% -$612K ﹤0.01% 7558
2018
Q1 		$1.03M Buy
5,656
+287
+5% +$64.5K ﹤0.01% 5167
2017
Q4 		$1.14M Buy
+5,369
New +$1.15M ﹤0.01% 4959
2017
Q2 		– Sell
-10,291
Closed -$2.02M – 9253
2017
Q1 		$2.55M Buy
10,291
+9,540
+1,270% +$2.34M ﹤0.01% 3298
2016
Q4 		$190K Sell
751
-2,881
-79% -$660K ﹤0.01% 8683
2016
Q3 		$740K Buy
+3,632
New +$452K ﹤0.01% 5361

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
DP
Diadema Partners Morristown, New Jersey $588M AUM 182.75% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's CRBP Position: Q1 2026 in Review

Susquehanna International Group increased its Corbus Pharmaceuticals (CRBP) stake by 46% in Q1 2026, buying an estimated $889K and bringing the position to 333,415 shares worth $3.13M. The position accounts for ﹤0.01% of the portfolio, ranked #5188.

Susquehanna International Group first reported a position in CRBP in Q3 2016 and has held it in 32 quarters since. 107 funds tracked by Wall St. Rank hold CRBP as of Q1 2026.

  • Susquehanna International Group held 333,415 shares of Corbus Pharmaceuticals worth $3.13M as of Q1 2026.
  • Susquehanna International Group bought 105,589 Corbus Pharmaceuticals shares in Q1 2026, an estimated $889K.
  • Corbus Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #5188 holding.
  • Susquehanna International Group first reported a position in Corbus Pharmaceuticals in Q3 2016 and has held it in 32 quarters since.
  • 107 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.